<SEC-DOCUMENT>0000904454-24-000667.txt : 20241223
<SEC-HEADER>0000904454-24-000667.hdr.sgml : 20241223
<ACCEPTANCE-DATETIME>20241223201749
ACCESSION NUMBER:		0000904454-24-000667
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20241223
DATE AS OF CHANGE:		20241223

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ASSEMBLY BIOSCIENCES, INC.
		CENTRAL INDEX KEY:			0001426800
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-85836
		FILM NUMBER:		241575384

	BUSINESS ADDRESS:	
		STREET 1:		TWO TOWER PLACE
		STREET 2:		7TH FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(833) 409-4583

	MAIL ADDRESS:	
		STREET 1:		TWO TOWER PLACE
		STREET 2:		7TH FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	VENTRUS BIOSCIENCES INC
		DATE OF NAME CHANGE:	20080211

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES, INC.
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				943047598
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILEAD SCIENCES INC
		DATE OF NAME CHANGE:	19930328
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0000904454-23-000577</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: GILEAD SCIENCES, INC. -->
          <cik>0000882095</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.001</securitiesClassTitle>
      <dateOfEvent>12/19/2024</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001426800</issuerCIK>
        <issuerCUSIP>045396108</issuerCUSIP>
        <issuerName>Assembly Biosciences, Inc.</issuerName>
        <address>
          <com:street1>Two Tower Place, 7th Floor</com:street1>
          <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Gilead Sciences, Inc.</personName>
          <personPhoneNum>650-574-3000</personPhoneNum>
          <personAddress>
            <com:street1>333 Lakeside Drive</com:street1>
            <com:city>Foster City</com:city>
            <com:stateOrCountry>CA</com:stateOrCountry>
            <com:zipCode>94404</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0000882095</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Gilead Sciences, Inc.</reportingPersonName>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>2209471.00</soleVotingPower>
        <sharedVotingPower>0.00</sharedVotingPower>
        <soleDispositivePower>2209471.00</soleDispositivePower>
        <sharedDispositivePower>0.00</sharedDispositivePower>
        <aggregateAmountOwned>2209471.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>29.9</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>Comment relating to row 13: Based upon 7,389,535 shares of common stock of the Issuer issued and outstanding, which 7,389,535 shares is equal to the sum of (i) 6,449,036 shares of common stock of the Issuer issued and outstanding as of December 18, 2024, as represented by the Issuer to Gilead Sciences, Inc. on December 18, 2024, plus (ii) 940,499 shares of common stock issued by the Issuer to Gilead Sciences, Inc. on December 19, 2024.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.001</securityTitle>
        <issuerName>Assembly Biosciences, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>Two Tower Place, 7th Floor</com:street1>
          <com:city>South San Francisco</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94080</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 2 ("Amendment No. 2") amends and supplements the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission (the "SEC") on October 25, 2023, as amended by Amendment No. 1 filed with the SEC on June 20, 2024 ("Amendment No. 1", and such Schedule 13D as amended by Amendment No. 1, the "Schedule 13D"), which relates to the common stock, par value $0.001 per share (the "Common Stock"), of Assembly Biosciences, Inc., a Delaware corporation (the "Issuer"). Unless otherwise indicated, all capitalized terms used herein shall have the meanings set forth in the Schedule 13D and, unless amended hereby, all information previously filed remains in effect.</commentText>
      </item1>
      <item2>
        <principalJob>Item 2(c) is amended to replace each reference to "Schedule I" with "Exhibit 99".</principalJob>
        <hasBeenConvicted>Item 2(d) is amended to replace the reference to "Schedule I" with "Exhibit 99".</hasBeenConvicted>
        <convictionDescription>Item 2(e) is amended to replace the reference to "Schedule I" with "Exhibit 99".</convictionDescription>
        <citizenship>Item 2(f) is amended to replace each reference to "Schedule I" with "Exhibit 99".</citizenship>
      </item2>
      <item3>
        <fundsSource>Item 3 is amended to add the following paragraph immediately following the last paragraph:

On December 19, 2024, Gilead purchased 940,499 shares of Common Stock from the Issuer at a purchase price of $21.37 per share, pursuant to the Purchase Agreement. The total consideration for such purchase was approximately $20.1 million, and such consideration was obtained from the available cash resources of Gilead.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>Item 4 is amended to add the following immediately following the last paragraph:

On December 19, 2024, Gilead purchased 940,499 shares of Common Stock from the Issuer at a purchase price of $21.37 per share, pursuant to Gilead's option to purchase additional shares of Common Stock from the Issuer in an amount that results in Gilead owning 29.9% of the Issuer's then outstanding voting capital stock, as set forth in the Purchase Agreement.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>Number of shares beneficially owned:  Gilead Sciences, Inc. - 2,209,471 Shares
Percent of class:  Gilead Sciences, Inc. - 29.9%
The percentage ownership was calculated based upon 7,389,535 shares of common stock of the Issuer issued and outstanding, which 7,389,535 shares is equal to the sum of (i) 6,449,036 shares of common stock of the Issuer issued and outstanding as of December 18, 2024, as represented by the Issuer to Gilead on December 18, 2024, plus (ii) 940,499 shares of common stock issued by the Issuer to Gilead on December 19, 2024.</percentageOfClassSecurities>
        <numberOfShares>(i) Sole power to vote or to direct the vote:  Gilead Sciences, Inc. - 2,209,471 shares
(ii) Shared power to vote or to direct the vote:  Gilead Sciences, Inc. - 0 shares
(iii) Sole power to dispose or to direct the disposition of:  Gilead Sciences, Inc. - 2,209,471 shares
(iv) Shared power to dispose or to direct the disposition of:  Gilead Sciences, Inc. - 0 shares

To the best knowledge of the Reporting Person, none of the individuals listed on Exhibit 99 beneficially owns any of the Issuer's Common Stock.

The Reporting Person beneficially owns a warrant to purchase 179,500 shares of Common Stock (the "Warrant") that was acquired from the Issuer on June 17, 2024. The Warrant held by the Reporting Person is subject to a limitation pursuant to which the Reporting Persons may not exercise the Warrant if such exercise would cause the Reporting Person to beneficially own Common Stock in an amount exceeding the "Beneficial Ownership Limitation" (as defined in the Warrant) then in effect. The Beneficial Ownership Limitation is subject to adjustment upon 61 days' notice by the holder of the Warrant to the Issuer and, as of the date of this Amendment No. 2, was 19.99% of the number of shares of Common Stock outstanding. As a result, none of the 179,500 shares of Common Stock underlying the Warrant are deemed to be beneficially owned by the Reporting Persons.</numberOfShares>
        <transactionDesc>Except as reported in this Amendment No. 2, neither the Reporting Person nor, to the best knowledge of the Reporting Person, any of the individuals listed on Exhibit 99 have effected any transactions in the Common Stock during the past sixty (60) days.</transactionDesc>
        <listOfShareholders>Not applicable.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Except as disclosed in Items 3 and 4 of this Amendment No. 2, there are no contracts, arrangements, understandings or relationships (legal or otherwise) to which the Reporting Person is a party with respect to the securities of the Issuer.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>Exhibit 99 - List of Executive Officers and Directors of Gilead Sciences, Inc.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Gilead Sciences, Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Andrew D. Dickinson</signature>
          <title>Andrew D. Dickinson, Chief Financial Officer</title>
          <date>12/23/2024</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>s13da_121924gilead-bod.htm
<DESCRIPTION>LIST OF EXECUTIVE OFFICERS AND DIRECTORS OF GILEAD SCIENCES, INC.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 99</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The name and present principal occupation of each of
the executive officers and directors of Gilead Sciences, Inc. are set forth below. Unless otherwise noted, each of these persons have
as their business address c/o Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, California 94404.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt"><FONT STYLE="font-size: 9pt"><B>Name</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Title</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Citizenship</B></FONT></TD>
    <TD STYLE="border-top: black 1pt solid; border-right: black 1pt solid; border-bottom: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt; text-align: center"><FONT STYLE="font-size: 9pt"><B>Principal Occupation and, if not employed by Gilead Sciences, Inc., Name, Principal Business and<BR>
Address of Employer</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Daniel P. O&rsquo;Day</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Chief Executive Officer, Chairman and Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Jacqueline K. Barton, Ph.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Professor Emerita, California Institute of Technology</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Jeffrey A. Bluestone, Ph.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">President and Chief Executive Officer, Sonoma Biotherapeutics</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Sandra J. Horning, M.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Retired Chief Medical Officer, Roche Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Kelly A. Kramer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Retired Executive Vice President and Chief Financial Officer, Cisco Systems, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Ted W. Love,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">M.D.</P></TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Chair of Board of Directors, Biotechnology Innovation Organization</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Harish Manwani</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Singapore</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Senior Operating Partner, Blackstone </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Javier J. Rodriguez</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Mexico</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Chief Executive Officer, DaVita, Inc.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Anthony Welters</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Director</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Chairman and Chief Executive Officer, CINQ Care</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Andrew D. Dickinson</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Chief Financial Officer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Johanna Mercier</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Chief Commercial Officer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Merdad V. Parsey, M.D., Ph.D.</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Chief Medical Officer</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">*</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: black 1pt solid; border-bottom: black 1pt solid; border-left: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 6.4pt">Deborah H. Telman</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">Executive Vice President, Corporate Affairs and General Counsel</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">United States</TD>
    <TD STYLE="border-bottom: black 1pt solid; border-right: black 1pt solid; padding-right: 6.4pt; padding-bottom: 6pt; padding-left: 5.9pt">*</TD></TR>
  </TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">* The present principal occupation for each of these individuals is officer
of Gilead Sciences, Inc. and officer, trustee and/or director of other affiliated entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
